Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen, a leading biotechnology firm based in Cambridge, Massachusetts, reported a disappointing outlook for 2025, resulting in significant effects on its stock price. On February 12, the company projected adjusted earnings per share (EPS) in the range of $15.25 to $16.25, with the midpoint lower than the anticipated consensus of...

Biogen Faces Stock Decline Amid Disappointing 2025 Earnings Forecast and Ongoing Challenges in Multiple Sclerosis Segment

Biogen's recent earnings forecast has sent shockwaves through the market, with a notable stock decline reflecting investor concerns. As the company grapples with challenges in its multiple sclerosis segment, can its ambitious plans for new drug launches and cost-cutting measures turn the tide?